Summary of research on whether voclosporin can be used in the treatment of skin diseases and related clinical applications

Voclosporin (Voclosporin) is a new type of cyclosporinA analogue, which regulates immune responses mainly by inhibiting T lymphocyte activation and cytokine release. Its core mechanism of action is to selectively block the calcineurin (calcineurin) signaling pathway and inhibit over-activated immune responses, so it has potential value in the treatment of autoimmune diseases and inflammation-related diseases. Although the efficacy of cyclosporin in kidney diseases has been fully proven, its application in the treatment of dermatology is still in the exploratory stage.

In dermatological clinical studies, the main focus of cyclosporin includes systemic lupus erythematosus with skin lesions, psoriasis, atopic dermatitis and other autoimmune skin diseases. Early studies and some phase II clinical trials have shown that cyclosporin can significantly improve skin inflammatory response, reduce skin lesion area and pruritus symptoms, and improve patients' quality of life. Compared with traditional cyclosporine, cyclosporine has optimized pharmacokinetics and safety, more stable oral absorption, smaller fluctuations in blood concentration, and relatively lower risk of nephrotoxicity with long-term use.

In actual clinical applications, cyclosporine is mainly used as a second-line or combination treatment drug for patients with refractory or moderately severe skin diseases. For example, in patients with psoriasis or atopic dermatitis, cyclosporin can be used as a short-term oral treatment to help quickly control skin inflammation when standard topical or systemic treatments are ineffective. Some studies have also explored the possibility of using it in combination with immunosuppressants or biological agents to improve the efficacy and prolong the remission period, while monitoring safety indicators such as liver and kidney function and blood pressure.

Overall, cyclosporin shows good clinical potential in the treatment of skin diseases, especially in patients with autoimmune and refractory skin diseases. Although the current marketed indications are mainly focused on renal diseases, with the accumulation of more clinical research and practice data, cyclosporin is expected to become an important auxiliary drug for dermatological immunotherapy. Future studies will further clarify dosing strategies, long-term safety and combination medication regimens to provide more precise and safe treatment options for patients with skin diseases.

Keyword tag:

Voclosporin,Voclosporin, skin diseases, treatment, clinical application, research summary, autoimmune skin diseases, safety

Reference materials:https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213716s000lbl.pdf